Acellular (aP) and whole-cell (wP) pertussis vaccines are presumed to have similar short-term (3 doses) of a primary series of a currently available aP or wP formulation. The primary outcome was based on the World Health Organization (WHO) clinical case definitions for pertussis. Study quality was assessed using the approach developed by the Child Health Epidemiology Research Group (CHERG). We determined overall effect sizes using random effects meta-analyses, stratified by vaccine (aP or wP) and study (efficacy or effectiveness) type.
Meta-analysis of two aP vaccine efficacy studies (assessing the three-component GlaxoSmithKline and five-component Sanofi-Pasteur formulations) yielded an overall aP vaccine efficacy of 84% (95% confidence interval (CI), 81-87%). Meta-analysis of three wP vaccine effectiveness studies (assessing the Behringwerke, Pasteur/Merieux, and SmithKline Beecham formulations) yielded an overall wP vaccine effectiveness of 94% (95% CI, 88-97%) (both I2=0%).
Although all contemporary aP and wP formulations protect against pertussis disease, in this meta-analysis the point estimate for short-term protective effect against WHO-defined pertussis in young children was lower for currently available aP vaccines than wP vaccines.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail email@example.com.
Authors:Fulton TR1, Phadke VK2, Orenstein WA3, Hinman AR4, Johnson WD5, Omer SB6.
Journal:Clin Infect Dis. 2016